With regard to the development of ibrutinib resistance in CLL patients, S707F point mutations have been detected in resistant cells without mutations in position A708 [5–7], in one case even in pretreatment samples before the initiation of targeted inhibition of Btk [6]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.